Mass Spectrometric Immunoassay for Parathyroid Hormone Related Protein (PTHrP)
Many cancers, including prostate, breast and lung express parathyroid hormone related protein (PTHrP). Despite the common tumor overexpression of PTHrP, serum levels of PTHrP are not commonly elevated in affected patients. They postulate that the reasons for the discrepancy between tissue and serum measurements of PTHrP are the inadequate sensitivity and specificity of current PTHrP serum assays. To improve the clinical value of PTHrP serum assays for the cancer patient, they are developing a new generation of novel and ultrasensitive PTHrP serum immunoassays based on immunoaffinity purification, nanospray liquid chromatography tandem mass spectrometry (LC/MS/MS) and accelerator mass spectrometry (AMS).
- Research Organization:
- Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States)
- Sponsoring Organization:
- USDOE Office of Defense Programs (DP) (US)
- DOE Contract Number:
- W-7405-Eng-48
- OSTI ID:
- 793940
- Report Number(s):
- UCRL-JC-139327; TRN: US0300657
- Resource Relation:
- Conference: 48th American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics, Long Beach, CA (US), 06/11/2000--06/15/2000; Other Information: PBD: 16 Jun 2000
- Country of Publication:
- United States
- Language:
- English
Similar Records
Structural Basis for Antibody Discrimination between Two Hormones That Recognize the Parathyroid Hormone Receptor
Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo